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Introduction: Dronedarone, a benzofuran derivative with a structure similar to amiodarone, 
has been developed as a potential therapy for patients with atrial fibrillation.
Aim: To review the published evidence regarding the efficacy and safety of dronedarone use 
in patients with atrial fibrillation.
Evidence review: Available evidence suggests that dronedarone 400 mg orally twice daily 
can lengthen the time to and decrease the overall recurrence of atrial fibrillation compared with 
placebo. Dronedarone may reduce risk of mortality and cardiovascular hospitalization. Patients 
with atrial fibrillation receiving dronedarone had improved ventricular rate control compared 
with patients receiving placebo. Dronedarone is associated with few serious adverse events 
except, notably, in patients with decompensated heart failure.
Place in therapy: Dronedarone may have a role in rate and rhythm control for patients with 
atrial fibrillation. Dronedarone can reduce unique, but potentially serious, end points in patients 
with atrial fibrillation. Despite this, the exact role of dronedarone in the management of patients 
with atrial fibrillation continues to emerge. It remains uncertain if dronedarone should be consid-
ered a primary treatment strategy for atrial fibrillation. Dronedarone should not be administered 
to patients with decompensated heart failure.
Conclusion: Dronedarone is a unique drug that may serve a key role to treat patients with 
atrial fibrillation.
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Core evidence clinical impact summary for dronedarone
Outcome 
measure
Evidence Implications
Disease-oriented 
evidence
DAFNE Use of dronedarone was associated with a longer time to atrial 
  fibrillation recurrence; likewise, patients receiving dronedarone, 
400 mg orally twice daily, were more likely to maintain sinus 
rhythm compared with patients receiving placebo
EURIDIS and 
ADONIS
Dronedarone 400 mg orally twice daily lengthened the time to 
atrial fibrillation recurrence, as well as symptoms associated 
with atrial fibrillation, compared with placebo
DIONYSOS More patients on dronedarone had atrial fibrillation recurrence 
or stopped the drug due to intolerance or lack of efficacy 
compared with patients receiving amiodarone
ERATO Dronedarone use was associated with decrease in ventricular 
rate, both at rest and with exercise
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Introduction
Pharmacologic management is the primary means by 
which patients with atrial fibrillation are treated. Results 
of large, randomized, controlled clinical trials have dem-
onstrated the influence of rate control and rhythm control 
strategies1,2 on important measurable outcomes but, despite 
the wealth of data, a universal treatment approach does 
not exist. Individualized management strategies, based 
on a composite of studies weighing the risks and benefits 
of rate control, rhythm control, and anticoagulation, are 
required to best treat each patient with this atrial fibrilla-
tion. In addition, catheter ablation is gaining approval in 
the management of specific patient group who have atrial 
fibrillation.
Antiarrhythmic drug therapy that theoretically may aid 
in maintaining sinus rhythm and thereby improve a host 
of clinical end points is considered by some to be a key 
component in managing patients with atrial fibrillation. 
To date, however, clinical trials have not demonstrated any 
specific value of an antiarrhythmic drug strategy on hard 
end points such as mortality and hospitalization. Antiar-
rhythmic drugs may have inherent risks that outweigh 
their benefits regarding these end points, but perhaps the 
real reasons to treat atrial fibrillation still needs to be 
better clarified.
Recently, as a result of several controlled clinical trials, a 
novel antiarrhythmic drug, dronedarone, has gained approval 
for use in patients with atrial fibrillation. The data, however, 
raise questions regarding the philosophy behind treating 
patients with atrial fibrillation, particularly regarding the use 
of an antiarrhythmic drug. This article addresses the role of 
dronedarone in the management of atrial fibrillation and shows 
how dronedarone may potentially augment our ability to better 
affect clinical outcomes in patients with this condition.
Why treat atrial fibrillation?
Reduction in symptoms, enhanced ability to perform activi-
ties of daily living, and overall improved quality of life are 
critical issues that form the basis of present day therapy for 
patients with atrial fibrillation. These issues receive little 
attention in clinical studies. Mortality has been studied as an 
end point in several large trials and, no doubt, atrial fibrilla-
tion has been associated with greater risk of death.3–5
Some studies simply look at time to first atrial fibril-
lation recurrence, whereas others define atrial fibrillation 
burden. Many episodes of atrial fibrillation, however, go 
unrecognized, are of brief duration, or have little import. 
Although these measures may help discern the antiar-
rhythmic efficacy of a drug, they provide little informa-
tion about how to treat the underlying problem. Rate and 
rhythm control strategies have been tested and compared, 
but these do not address a comprehensive approach to the 
management of patients with atrial fibrillation since rarely 
is either strategy the lone approach. In fact, we have learned 
that neither approach is necessarily superior with regard 
to risk of stroke, survival, or any important clinical end 
point.1,2,6 Irrespective of rate and rhythm controls, recent 
data support a unique role for dronedarone to treat patients 
with atrial fibrillation.7
Dronedarone – pharmacologic  
and electrophysiologic properties
Current antiarrhythmic drug strategies to help manage atrial 
fibrillation and maintain sinus rhythm tend to focus on the 
use of amiodarone, among other drugs. Amiodarone, how-
ever, is not approved for this purpose in the United States. 
Although perhaps dronedarone is the most efficacious drug 
to maintain sinus rhythm and control ventricular rate should 
atrial fibrillation recur, its use comes with the risk of adverse 
(Continued)
Outcome 
measure
Evidence Implications
ATHENA The use of dronedarone was associated with decreased 
cardiovascular deaths and arrhythmic deaths compared with 
placebo. There was also a decrease in hospitalizations for atrial 
fibrillation and acute coronary syndrome in patients receiving 
dronedarone compared with placebo
ANDROMEDA Dronedarone 400 mg orally twice daily was associated with an 
acute increase in death in patients with new or worsening New 
York Heart Association functional class III or IV heart failure
Patient-oriented 
evidence
Economic  
evidence
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effects that make the drug untenable to many treating physi-
cians and patients alike.
Dronedarone is structurally similar to amiodarone but 
lacks an iodine moiety. As such, it holds some properties 
akin to amiodarone, but has others that make dronedarone 
unique. Based on the Vaughan–Williams classification,8 
dronedarone, similar to amiodarone, is considered a class III 
antiarrhythmic drug. Dronedarone can decrease sinus rate, 
increase Wenckebach cycle length, the AH interval, atrial, 
atrioventricular node, and ventricular effective refractory 
periods,9 as well as inhibit β-adrenoreceptor stimulation,10,11 
at least in canine models. Rat and pig models of coronary 
ischemia have also demonstrated dronedarone to reduce 
ventricular fibrillation episodes at low doses and eliminate 
ventricular fibrillation and mortality at higher doses,12 as well 
as reduce ventricular tachycardia and premature ventricular 
contractions.13 Upon reperfusion, dronedarone reduced mor-
tality at low doses and eliminated ventricular fibrillation or 
mortality at higher doses.12 In comparison, during ischemia, 
high doses of amiodarone were shown to reduce the incidence 
of mortality12 and ventricular fibrillation (although not to a 
significant degree), ventricular tachycardia, and premature 
ventricular contractions.13
Dronedarone has demonstrated an inhibitory effect on the 
following potassium channels: rapid delayed rectifier, slow 
delayed rectifier, acetylcholine-activated, inward rectifier, 
and sustained currents.14–16 There was reduction of inward 
currents of the rapid sodium channel and L-type and T-type 
calcium currents.8 In addition, suppression of automaticity 
of the sinoatrial node due to prolongation of action potential 
duration and change in slope of phase 4 depolarization has 
been observed.17 α- and β-adrenoreceptor antagonism have 
been seen.10,18
The electrophysiologic properties of dronedarone during 
chronic administration may differ from those of amiodarone. 
In a patch clamp study of canine Purkinje fibers, papillary 
muscle, and ventricular myocytes, QT prolongation and 
lengthening of the action potential duration, seen with amio-
darone, were not observed with dronedarone.19 This differ-
ence may be related to lack of accumulation of metabolites 
with dronedarone as opposed to the effects of the parent drug. 
Alternatively, a rabbit model evaluating the long-term use of 
these drugs showed both increased action potential duration 
and effective refractory period.20
Although dronedarone is devoid of many of the concern-
ing side effects associated with amiodarone, it may also 
lack the antiarrhythmic potency of amiodarone. Compared 
with amiodarone, dronedarone is less lipophilic, has less 
tissue accumulation, and has a shorter elimination half-life 
(27–31 hours). The drug is eliminated mainly through the GI 
tract, as opposed to the hepatic metabolism of amiodarone. 
Dronedarone requires twice daily dosing. There is no need 
for an aggressive loading regimen, and steady state is reached 
within 4–8 days of initiation.8 N-debutyldronedarone, the 
major metabolite of dronedarone, exhibits similar characteris-
tics to dronedarone’s antiarrhythmic drug effect. Dronedarone 
has few drug–drug interactions and is rarely proarrhythmic. 
As such it can be initiated without need for hospitalization 
in properly selected patients.
Dronedarone is a moderate inhibitor of CYP3A4 and 
a weak inhibitor of CYP2D6, and thereby impacts the 
metabolism of some drugs, such as statins, calcium-channel 
antagonists, β-blockers, and digoxin.8 There can be drugs 
that affect metabolism (such as tacrolimus). Although 
dronedarone can increase creatinine, it does not affect the 
glomerular filtration rate.8
Controlled clinical trials showing 
antiarrhythmic efficacy  
of dronedarone
Rhythm control
Dronedarone Atrial Fibrillation study after  
Electrical Cardioversion
The Dronedarone Atrial Fibrillation study after Electrical 
Cardioversion (DAFNE) was a mutlticountry, double-blind, 
placebo-controlled study that determined the proper dose 
of dronedarone to prevent recurring atrial fibrillation after 
cardioversion.21 Patients with persistent atrial   fibrillation 
of 72 hours to 12 months of duration anticoagulated with 
warfarin for at least 3 weeks were randomized to one of the 
following: dronedarone (400, 600, or 800 mg twice daily) or 
placebo. Patients with more than 2   cardioversions in the last 
6 months, those with a reversible cause of atrial   fibrillation, 
recent myocardial ischemia, QT interval .500 ms or his-
tory of torsades de pointes, New York Heart   Association 
(NYHA) Functional Class III or IV heart failure, left 
  ventricular   ejection   fraction ,35%, or those with an implant-
able cardioverter defibrillator were excluded from the study. 
Electrical cardioversion was performed if patients remained 
in atrial fibrillation 5–7 days after starting therapy; the 
therapy continued for 6 months if patients were successfully 
cardioverted.
One hundred ninety-nine patients in whom sinus rhythm 
was restored were followed with transtelephonic electrocar-
diogram (ECG) monitoring throughout the trial. The median Core Evidence 2010:5 submit your manuscript | www.dovepress.com
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time to atrial fibrillation recurrence of at least 10-minute 
duration was 5.3 days in the placebo group and 60 days in 
the dronedarone 400 mg twice daily group (relative risk 
  reduction, 55%; 95% confidence interval [CI], 72–28; 
P = 0.001). There were no significant differences in the 
other groups. Thirty-five percent of those taking dronedarone 
400 mg twice daily maintained sinus rhythm at 6 months 
vs 10% in the placebo group. There was greater incidence 
of conversion to sinus rhythm in the dronedarone groups 
(5.8% with 400 mg twice daily, 8.2% with 600 mg twice 
daily, and 14.8% with 800 mg twice daily) compared with 
3.1% with placebo (P = 0.026), but there was no difference 
in the   success of electrical cardioversion between the groups. 
Although more efficacious, patients in the dronedarone 
groups were more likely to discontinue therapy (3.9%, 400 
mg twice daily; 7.6%, 600 mg twice daily; and 22.6%, 800 
mg twice daily) compared with placebo (0%). This was 
usually due to gastrointestinal complaints, specifically, 
diarrhea.
Several important issues regarding the use of dronedarone 
emerged from this study. Oral administration of dronedarone 
400 mg twice daily could safely maintain sinus rhythm in 
patients with previous atrial fibrillation even if only a small 
percent of patients actually responded to the drug compared 
with placebo based on the criteria of 10-minute durations 
of atrial fibrillation. Side effects were dose dependent, and 
although tolerable and not as severe as those experienced 
with some other antiarrhythmic drugs, they may limit the 
benefits of the drug regarding symptom reduction. This is the 
reason to limit dronedarone dosing to 400 mg twice daily. 
From this point, no other doses of dronedarone have been 
used in clinical trials.
EURIDIS and ADONIS
The European Trial in Atrial Fibrillation or Flutter Patients 
Receiving Dronedarone for the Maintenance of Sinus Rhythm 
(EURIDIS) and the American-Australian-African Trial with 
Dronedarone in Atrial Fibrillation or Flutter Patients for the 
Maintenance of Sinus Rhythm (ADONIS) were multicenter, 
double-blind trials that sought to determine if dronedarone 
was superior to placebo in maintaining sinus rhythm after 
conversion from atrial flutter or fibrillation.22 These trials 
were sponsored by Sanofi-Aventis. They also managed and 
analyzed the data.
Enrolled patients had at least one episode of atrial 
fibrillation in the prior 3 months and were in sinus rhythm 
for at least 1 hour before randomization. Participants in 
the study had a mean age of 63 years and were mostly 
men. More than 50% had hypertension. Patients were 
randomized 2:1 to dronedarone 400 mg twice daily or 
placebo in addition to concomitant therapy, including 
β-blockers, calcium-channel antagonists, and digoxin. 
Patients with permanent atrial fibrillation, women of 
child-bearing age not using birth control, patients with a 
history of torsades de pointes, persistent heart rate ,50 
beats per minute, a PR interval $0.28 s, second degree 
or more advanced heart block, those taking class I or III 
antiarrhythmic drugs, NYHA class III or IV heart failure or   
creatinine .1.7 mg/dL were excluded.
EURIDIS randomized 411 patients to dronedarone and 
201 patients to placebo. The median time to recurrence of 
atrial fibrillation lasting at least 10 minutes was 96 days in 
the dronedarone group vs 41 days in the placebo group; 37% 
of patients in the dronedarone group and 48% in the placebo 
arm were symptomatic (P = 0.006). At 1 year, 67% of patients 
on dronedarone had a recurrence compared with 78% receiv-
ing placebo (hazard ratio [HR] = 0.78; 95% CI, 0.64–0.96; 
P = 0.01). Post hoc analysis showed more patients in the 
placebo arm had been hospitalized or died at 12 months 
compared with dronedarone (32% vs 21%, HR = 0.66; 95% 
CI, 0.47–0.93; P = 0.02).
ADONIS randomized 417 patients to dronedarone 
and 208 patients to placebo. The median time to recur-
rence was 158 days in the dronedarone group compared 
with 59 days in the placebo group; 38% of patients in the 
dronedarone group and 45% in the placebo group were 
symptomatic (P = 0.02). At 1 year, 61% of patients on 
dronedarone had recurrence compared with 73% receiv-
ing placebo (HR = 0.73; 95% CI, 0.59–0.89; P = 0.002). 
Post hoc analysis showed no difference between the groups 
when comparing hospitalizations or death at 12 months 
(P = 0.22).
Although EURIDIS and ADONIS showed that drone-
darone can lengthen the time to first recurrence of atrial 
fibrillation, these data did not indicate that most patients 
taking dronedarone remained arrhythmia free; a   substantial 
number of participants in the study had recurrence at 1 year. 
In addition, all recurrent episodes may not have been detected, 
particularly if patients were asymptomatic and did not 
transmit an ECG transtelephonically. Furthermore, time to 
the first recurrence did not necessarily indicate an improve-
ment in frequency or duration of atrial fibrillation episodes. 
These data do not indicate a strong antiarrhythmic effect 
of dronedarone, and these data cannot be compared with 
the antiarrhythmic drug efficacy of any other drug as this 
population is unique.Core Evidence 2010:5 submit your manuscript | www.dovepress.com
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DIONYSOS
The Randomized, Double-Blind Trial to Evaluate the Effi-
cacy and Safety of Dronedarone (400 mg twice daily) vs 
amiodarone (600 mg everyday for 28 days, then 200 mg 
everyday thereafter) for at least 6 months for the mainte-
nance of sinus rhythm in patients with atrial fibrillation 
  (DIONYSOS) study sought to directly compare the risks 
and benefits of dronedarone and amiodarone by measuring 
efficacy with 12 lead ECGs to document atrial fibrillation 
recurrence and safety of the 2 drugs.23
A total of 504 patients with atrial fibrillation for at least 
72 hours were randomized to dronedarone 400 mg twice daily 
(N = 249) or amiodarone 600 mg daily for 28 days, and then 
200 mg thereafter (N = 255). Patients were excluded if they 
had received amiodarone previously or had   contraindications 
to its use, as well as if they had severe congestive heart   failure 
(including those with NYHA class III or IV symptoms) or 
high-degree atrioventricular block. Patients who did not 
achieve sinus rhythm after initiation of the study drug under-
went electrical cardioversion. Patients who failed electrical 
cardioversion or failed spontaneous conversion after drug 
initiation were considered to have atrial fibrillation recurrence 
in the analysis. Most participants in the study were males, 
had persistent atrial fibrillation, had hypertension, and were 
receiving oral anticoagulants and β-blockers at the time of 
enrollment.
During a mean follow up of 7 months, 75.1% of patients 
receiving dronedarone had either recurrence of atrial fibril-
lation or stopped the medication due to intolerance or lack 
of efficacy compared with 55.8% in the amiodarone arm 
(HR = 1.59; 95% CI, 1.28–1.98; P , 0.0001). More patients 
had recurrent atrial fibrillation with dronedarone compared 
with amiodarone (63.5% vs 42%). Premature drug discon-
tinuation occurred with both drugs (10.4% with dronedarone 
vs 13.3% with amiodarone).
Adverse event rates were high for both the drugs 
(39.3% with dronedarone vs 44.5% with amiodarone; 
HR = 0.80; 95% CI, 0.60–1.07; P = 0.13). However, there 
were fewer thyroid, neurological, skin, and eye events with 
dronedarone compared with amiodarone. Similar to other 
studies, dronedarone was associated with more adverse 
gastrointestinal events than amiodarone. Participants 
receiving dronedarone had less reduction in heart rate, had 
fewer QTc prolongations beyond 500 ms, and had fewer 
elevated international normalized ratio (INR) compared 
with those on amiodarone. Although dronedarone was 
not as efficacious as amiodarone in maintaining sinus 
rhythm, considering its lower risk of side effects, it may 
be reasonable to consider the use of dronedarone before 
initiating amiodarone.
Unfortunately, 75% of those randomized to dronedarone 
had recurrent atrial fibrillation, did not convert to sinus 
rhythm, or had to stop the drug due to intolerance or lack of 
efficacy. Even higher rates of atrial fibrillation recurrence 
may have been present as recurrence was dependent on 
intermittent 12 lead ECG recordings. On the other hand, this 
strategy of monitoring seems more representative of what 
actually occurs in clinical practice, and it is possible that 
short bouts of atrial fibrillation detected by transtelephonic 
monitoring may not be clinically relevant. Despite higher risk 
of side effects, amiodarone was more effective to maintain 
sinus rhythm. Although not reported, in long-term follow-up, 
amiodarone may have a greater risk for severe or potentially 
life-threatening adverse effects.
Dronedarone vs amiodarone rhythm  
control – meta-analysis
A meta-analysis comparing the efficacy and safety of drone-
darone with amiodarone to prevent recurrent atrial fibrillation 
was recently published.24 Four dronedarone studies and 4 
amiodarone studies were included for indirect comparison. 
One study, DIONYSOS, was included for direct comparison. 
Although dronedarone and amiodarone could prevent atrial 
fibrillation recurrence compared with placebo (odds ratio 
[OR] = 0.79; 95% CI, 0.33–1.87 and OR = 0.12; 95% CI, 
0.08–0.19, respectively), when compared to each other, amio-
darone was more potent (OR = 0.16; 95% CI, 0.06–0.42). 
In terms of safety, dronedarone was more favorable than 
amiodarone, which was associated with higher odds of study 
drug termination (OR = 6.65; 95% CI, 1.13–39.3). These data 
highlight the efficacy of amiodarone as an antiarrhythmic 
drug and indicate that dronedarone is not as effective, at least 
in the populations studied.
It should be noted, however, that all meta-analyses are 
subject to specific weaknesses of study design and end-point 
monitoring. As we discussed earlier, time to recurrence of 
atrial fibrillation may not be the most appropriate end point 
to consider. Depending on how the data are analyzed and 
the specific end point selected, dronedarone may or may not 
appear to be a more successful drug in the management of 
atrial fibrillation. Clinically, it is hard to incorporate sophis-
ticated statistical manipulations to better understand   efficacy. 
In reality, if a patient has recurrent symptomatic atrial 
fibrillation, even if it occurs several months or even years 
later, it may be interpreted by the clinician and the patient 
as a failure of the drug. In selected patients, maintenance of Core Evidence 2010:5 submit your manuscript | www.dovepress.com
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sinus rhythm may have value and may be best achieved by 
an ablation strategy. When combining clinical studies that 
evaluate antiarrhythmic drugs that have   different statistical 
methodologies and end points, it can be quite difficult to 
draw meaningful conclusions. It stated that dronedarone 
may have antiarrhythmic efficacy to prevent atrial   fibrillation 
  recurrence, but it does not appear to be as effective as 
amiodarone and, considering the side effects of the drugs, 
it remains uncertain whether it will establish itself as a drug 
that is superior to amiodarone.
Rate control
The efficacy and safety of dronedarone for the control of 
ventricular rate during atrial fibrillation (ERATO) study was a 
multicenter, double-blind, placebo-controlled trial conducted 
to determine the efficacy of dronedarone to control ventricu-
lar response in patients with permanent atrial fibrillation.25 
After 2 weeks of screening, patients with   symptomatic and 
  permanent atrial fibrillation with a ventricular rate $80 
beats per minute on a 6-second rhythm strip were random-
ized in a 1:1 fashion to dronedarone 400 mg twice daily 
(N = 85) or placebo (N = 89), in addition to their usual 
therapy. At baseline, less than 50% of patients were taking 
calcium-channel antagonists or digoxin and just over 50% 
were   taking β-blockers. Patients were excluded if they were 
taking other antiarrhythmic drugs, had unstable angina, a 
history of torsades de pointes, third-degree heart block or 
sinus node disease, or NYHA Functional Class III or IV 
heart failure.
At day 14, patients in the dronedarone arm had a ven-
tricular rate 11 beats per minute on 24-hour Holter monitor 
compared with placebo (P , 0.0001), not accounted for by 
the use of other medications. When added to β-blockers or 
digoxin, dronedarone had a significant impact on decreas-
ing heart rate compared with placebo (−14.9 vs −11.5 beats 
per minute, P , 0.0001), but the change was not significant 
in conjunction with calcium-channel antagonists (−5.1 
beats per minute, P = 0.1). The control of ventricular rate 
with dronedarone over placebo persisted with both sub-
maximal and maximal exercise testing at day 14 compared 
with day 0 (P , 0.0001). At 4 months, there continued 
to be control of the ventricular rate over a 24-hour period 
in the dronedarone arm compared with the placebo arm 
(P , 0.001). Few adverse events occurred in the study: 
there was one death of a patient with congenital heart dis-
ease and an abnormal EKG, which should have precluded 
entry into the study (EKG findings were not described) in 
the dronedarone arm, 3 myocardial infarctions (1 in the 
dronedarone arm, 2 in the placebo arm), 1 episode of heart 
failure in the dronedarone arm, and 1 case of unstable 
angina in the placebo arm.
Although not their primary end points, other dronedarone 
trials showed the value of the drug to control ventricular rate 
if atrial fibrillation were to recur. In DAFNE, patients in the 
dronedarone groups had a significant reduction in ventricular 
rate response at the time of recurrent atrial fibrillation com-
pared with placebo (P = 0.0001).21 Similarly, both EURIDIS 
and ADONIS showed similar benefit in patients with 
recurrent atrial fibrillation receiving dronedarone and 
placebo (ventricular rate 102 ± 25 beats per minute in 
the dronedarone group and 118 ± 29 beats per minute in 
the placebo group in EURODIS, P , 0.001); 105 ± 27 
beats per minute in the dronedarone group and 117 ± 32 
beats per minute in the placebo group in ADONIS, 
P , 0.001.22
These data suggest that dronedarone may have a 
beneficial effect for patients if atrial fibrillation were to 
recur. The mechanism by which dronedarone controls 
the ventricular response rate in atrial fibrillation remains 
uncertain, but   nevertheless, part of symptom reduction in 
patients who report improvement when taking dronedarone 
could be, in part, due to this effect alone. The mechanism 
by which   dronedarone affects ventricular rate may be by 
alteration in atrial fibrillation cycle length or by its effect 
on AV conduction. Important to realize, however, is that the 
patients enrolled in ERATO did not have a rapid ventricular 
response to begin with: patients in placebo had a heart rate 
of approximately 90 beats per minute and those randomized 
to dronedarone started with a heart rate of approximately 
85 beats per   minute. Further, the proper ventricular rate 
in atrial fibrillation remains uncertain.1,26–28 Nevertheless, 
these data suggest that dronedarone may be a drug that 
could be used individually rather than in   combination with 
other   rate-controlling medications, such as calcium-channel 
antagonists or β-adrenergic blockers. Alternatively, patients 
who tend to be candidates for dronedarone may require one 
of these medications in any event, at least for treatment 
of comorbid conditions such as hypertension or coronary 
artery disease.
Novel end points of dronedarone
A Placebo-Controlled, Double-Blind, Parallel Arm Trial 
to Assess the Efficacy of Dronedarone 400 mg bid for the 
Prevention of Cardiovascular Hospitalization or Death from 
Any Cause in Patients with Atrial Fibrillation/Atrial   Flutter 
(ATHENA) was conducted to determine if   dronedarone could Core Evidence 2010:5 submit your manuscript | www.dovepress.com
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decrease the composite end point of cardiovascular hospital-
izations or death in patients with atrial   fibrillation.7 The trial 
was sponsored by Sanofi-Aventis, who also   collected, man-
aged, and analyzed the data. It is the   pivotal trial that ulti-
mately helped the drug gain approval for use in the United 
States. ATHENA was as large as the Atrial Fibrillation 
Follow-up Investigation of Rhythm   Management (AFFIRM) 
trial and was one of the largest trials that studied the use of 
an antiarrhythmic drug to treat atrial fibrillation.
Patients with paroxysmal or persistent atrial fibrillation or 
flutter were included in the study if they were at least 70 years 
old or had other comorbid conditions, such as hypertension, 
diabetes, stroke or transient ischemic attack, or left ven-
tricular ejection fraction #40%. Dronedarone therapy was 
initiated in 2,301 patients and placebo was initiated in 2,327; 
median follow-up was 21 ± 5 months. Almost all patients 
(n = 4,544) had left ventricular function evaluation; only 
4% had a left ventricular ejection fraction ,35% and 12% 
had a left ventricular ejection fraction ,45%. Most patients 
were taking a β-blocker, an angiotensin-converting enzyme 
inhibitor or an angiotensin receptor blocker therapy at the 
time of enrollment.
Of those randomized to dronedarone, 675 were hospit-
alized and 59 died; of those who received placebo, 859 
had a   cardiovascular event requiring hospitalization and 
58 died (HR = 0.76; 95% CI, 0.69–0.84; P , 0.001). 
Cardiovascular deaths were fewer in the dronedarone arm 
compared with placebo (HR = 0.71; 95% CI, 0.51–0.98; 
P = 0.03), as were deaths from arrhythmia (HR = 0.55; 95% 
CI, 0.34–0.88; P = 0.01). There were fewer hospitalizations 
for atrial fibrillation and acute coronary syndrome in the 
dronedarone group compared with placebo (P , 0.001 and 
P = 0.03, respectively). In the ATHENA trial, there were 
more treatment-emergent adverse events in the dronedarone 
group compared with placebo (P = 0.05), including cardiac 
events, QT-interval prolongation, gastrointestinal events, 
rash, and increase in serum creatinine (all P , 0.05), which 
led to premature discontinuation of the study drug more with 
dronedarone than placebo (P , 0.001).
A post hoc analysis of the ATHENA data determined 
the impact of dronedarone on stroke.29 The baseline risk of 
stroke was based upon the CHADS2 score for each participant 
(mean score of 2 in the placebo and dronedarone groups), 
and the occurrence of stroke was determined by review of 
hospitalization and death records. Only 60% of patients were 
  receiving oral anticoagulation at the time of enrollment, and 
this remained steady during follow-up. Participants in both 
arms were considered to have a therapeutic INR of 2–3 no 
more than 50% of the time; the anticoagulation status at the 
time of an event was not reported. There were fewer total 
strokes and strokes or transient ischemic attacks combined 
in the group receiving dronedarone compared with placebo 
(P = 0.03 for both). When the combined end points of stroke, 
acute coronary syndrome, and death or cardiovascular death 
were studied, favorable results were also seen with drone-
darone compared with placebo (P = 0.002 and P , 0.001, 
respectively).
ATHENA was a large, multicenter trial that indicated 
that a unique and important clinical end point could 
be achieved with dronedarone 400 mg twice daily. It is 
important to recognize that none of these patients had 
acute exacerbations of congestive heart failure when the 
drug was initiated. Furthermore, this study was unique as 
an antiarrhythmic drug study for atrial fibrillation, in that 
it did not consider the recurrence rates of atrial fibrillation 
or even rate control as primary objectives of the study. The 
combined clinical end point, while clinically important, may 
have little impact on the utility of this drug as the key pur-
pose of treating patients with atrial fibrillation is to improve 
symptoms, reduce the risk of stroke, and improve quality of 
life. However, dronedarone did reduce hospitalizations for 
atrial fibrillation, and this alone may improve patients’ qual-
ity of life. From an economic standpoint, this may also be a 
useful drug given the epidemic of atrial fibrillation. On the 
other hand, this information is quite noteworthy because no 
other antiarrhythmic drug to date has shown any favorable 
impact on mortality or hospitalization due to cardiovascular 
causes. In this sense, dronedarone is potentially attractive 
for patients with atrial fibrillation as it may affect several 
important clinical outcomes.
In ATHENA, dronedarone was used in a specific popu-
lation of elderly patients who had modest CHADS2 scores. 
Although there was a reduction in stroke and acute coronary 
syndromes in the dronedarone arm, it should also be noted 
that not all patients received oral anticoagulation during the 
study and it is not clear if patients were adequately antico-
agulated at the time of a clinical event. Similarly, it is unclear 
the percentage of participants who maintained sinus rhythm 
in ATHENA as this was not a study end point. It is possible 
that patients who maintained sinus rhythm were less likely 
to have a stroke.
Based on the results of the ATHENA trial, dronedarone 
appears to be relatively safe despite the greater premature 
discontinuation of the drug compared to placebo. The 
risk of major side effects that occur or can occur with 
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monary toxicity, and neurological toxicity did not occur 
with dronedarone. In fact, compared with placebo, drone-
darone had no   substantial serious adverse side effects. That 
stated, there are potential side effects that can occur with 
dronedarone. These include gastrointestinal intolerance, 
shortness of breath, and elevation in creatinine which is 
not associated with renal dysfunction and may be of no 
clinical significance.
Controlled clinical trials showing 
potential risks of dronedarone
The Antiarrhythmic Trial with Dronedarone in   Moderate to 
Severe CHF Evaluating Morbidity Decrease (  ANDROMEDA) 
was a multicenter, double-blind study that sought to deter-
mine if the use of dronedarone 400 mg orally twice daily 
could reduce the rate of heart failure hospitalizations, as 
well as mortality, by reducing deaths due to   arrhythmia in 
627 patients hospitalized with new or worsening NYHA 
Functional Class III or IV heart failure with a wall motion 
index of #1.2, the equivalent of a left ventricular   ejection 
fraction of 35%.30 Among other criteria, patients were 
excluded if they had an acute myocardial infarction, 
  bradycardia, or were receiving class I or III antiarrhythmic 
drugs. Only a quarter of the patients had atrial fibrillation at 
the time of randomization; 40% reported a history of atrial 
fibrillation.
The study was stopped early (median follow-up of 
2 months) as 25 of the patients randomized to dronedarone 
(n = 310) died, whereas only 12 patients randomized to pla-
cebo (n = 317) did (HR = 2.13; 95% CI, 1.07–4.25; P = 0.03). 
There was no difference in deaths after an additional 6 months 
of follow-up: 42 patients on dronedarone and 39 patients on 
placebo had died (HR = 1.13; 95% CI, 0.73–1.74; P = 0.6). 
There was no difference in the primary end point of   all-cause 
mortality or hospitalization for heart failure between the 
2 groups with 53 events in participants receiving drone-
darone and 40 events in the placebo group at 2 months 
(HR = 1.38; 95% CI, 0.92–2.09; P = 0.12) and 74 events 
in the dronedarone arm and 72 events in the placebo arm 
after an additional 6-month follow-up (HR = 1.09; 95% CI, 
0.79–1.51; P = 0.6). More patients in the dronedarone arm 
were hospitalized for cardiovascular reasons compared with 
patients receiving placebo (P = 0.02). Based upon the results 
of this trial, dronedarone carries a boxed warning advising 
against the use of it in patients with NYHA Functional 
Class IV heart failure or NYHA Functional Class II and III 
heart failure with recent decompensation requiring hospital-
ization or referral to a heart failure clinic.
There are several important issues that must be rec-
ognized regarding this trial. As mentioned above, not all 
patients had atrial fibrillation, and thus, this was a trial that 
assessed the safety of dronedarone in patients with recent 
onset congestive heart failure and impaired left ventricular 
function. In sharp contrast to the ATHENA trial in which 
patients could have heart failure symptoms but were con-
sidered stable, patients in ANDROMEDA were acutely 
decompensated. In fact, in the ATHENA trial, patients with 
left ventricular ejection fractions ,35% were enrolled, 
reaching numbers similar to the number of participants in 
ANDROMEDA. In ATHENA, all patients with heart failure 
and low ventricular ejection fractions had atrial fibrillation 
in contrast to the ANDROMEDA trial. Nevertheless, these 
data raise red flags about the use of dronedarone in patients 
with congestive heart failure and impaired ventricular 
function. We advise against the use of dronedarone in 
these patients. The utility of dronedarone in patients with 
diastolic dysfunction and intact ejection fraction has not 
been directly studied to date.
Dronedarone in clinical practice
The data that have been reported thus far concerning 
dronedarone have been collected to better understand the 
effects of the drug on rate and rhythm control, hospital-
izations, and mortality. Many of these studies have been 
performed to determine if dronedarone can be utilized for 
a wide range of potential indications. These indications 
are only beginning to be understood, and the exact role 
of dronedarone to treat patients with atrial fibrillation 
remains uncertain.
To date, there have been no changes in the American 
College of Cardiology/American Heart Association Guide-
lines in regards to the use of dronedarone in the management 
of patients with atrial fibrillation.31 Some investigators have 
attempted to recommend a role for dronedarone based on 
the present data.32 On the other hand, the National Institute 
for Health and Clinical Excellence (NICE) in England and 
Wales has been asked to consider the addition of drone-
darone to their 2006 guidelines for atrial fibrillation man-
agement.33 The original assessment was that dronedarone 
should not be included in the updated guidelines as it has 
not shown important clinical utility in lieu of its potential 
costs.
The most recent preliminary appraisal consultation 
from the NICE committee, however, suggests dronedarone 
may be considered for the treatment of nonpermanent 
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by first-line therapy, and the patient has at least one of 
the following: hypertension requiring medications from 
at least 2 different classes; diabetes mellitus; previous 
transient ischemic attack, stroke, or systemic embolism; 
left atrial diameter of $50 mm; left ventricular ejection 
fraction #40%, or age $ 70 years without NYHA Func-
tional Class III or IV heart failure.34 Patients who do not 
meet these criteria and who are already on dronedarone 
will have the option to continue the drug until physicians 
choose to stop it.
At this time, physicians face the difficult decision of 
whether to initiate dronedarone based upon the results of 
individual controlled clinical trials that often included the use 
of other drugs to treat atrial fibrillation, such as β-blockers, 
calcium-channel antagonists, or digoxin. It is not clear that 
dronedarone has a role as a primary treatment strategy. Its 
use should be avoided in cases of decompensated NYHA 
Functional Class II or III heart failure, as well as NYHA 
Functional class IV heart failure. Patients who are receiving 
therapy for atrial fibrillation but still remain symptomatic 
and those with contraindications to amiodarone may derive 
benefit from dronedarone.
We consider that dronedarone has a role to treat patients 
with atrial fibrillation to potentially improve several hard 
outcomes, and improve functionality, quality of life by 
reducing episodes of atrial fibrillation, as well as their 
severity. To date, the drug has few concerning serious long-
term side effects and can be used for those patients with 
multiple   comorbidities, who have symptomatic, recurrent 
atrial fibrillation.
Dronedarone has advantages over other   antiarrhythmic 
drugs that may be used in the management of atrial   fibrillation. 
The properties of the drug allow it to be   initiated as an out-
patient and aggressive loading is not required. Although the 
drug is new to the market and cost may be   prohibitive for 
some patients, costs are oftentimes being   covered by   insurance 
companies who consider covering the drug a small price to 
pay in comparison to the cost of a potential hospitalization 
secondary to atrial fibrillation.
Future directions
Postmarket assessment and clinical hands-on experience are 
key issues that will determine the fate of dronedarone in clini-
cal practice. Initial experiences have been quite variable. Many 
patients have suffered recurrence of atrial fibrillation while tak-
ing dronedarone; this may be because patients who are placed 
on dronedarone have failed other antiarrhythmic agents. Alter-
natively, dronedarone may not be as good an antiarrhythmic 
drug as it is believed to be. Furthermore, no good data, with 
the exception of decrease in hospitalizations, exist to suggest 
that dronedarone can improve   symptoms and quality of life for 
patients. The risks and benefits of this drug in clinical practice 
remain uncertain and more data are needed. As data emerge, 
we will have a better grasp about which patient populations 
can benefit the most from this drug and which have the   greatest 
risk of side effects without gaining any substantial clinical 
benefit. In addition, we will begin to learn which patients 
already receiving therapy for atrial fibrillation, on their current 
regimen including antiarrhythmic agents, would benefit from 
switching to dronedarone.
Overall, results may be disappointing as patients and 
physicians realize that hospitalizations and mortality are 
not the end points most cared about and that reduction 
of symptoms and complications are the most highly 
regarded end points. In addition, long-term follow up may 
suggest that side effects and adverse effects are possible 
with dronedarone. Twice daily dosing of the drug may 
prove to decrease drug regimen adherence compared with 
the once daily dosing of   amiodarone. Finally, the cost 
of dronedarone may be   prohibitive for some patients so 
that the drug is not an option for them. Costs, however, 
are difficult to gauge as the price varies by location, 
insurance plan, and other factors.
Conclusion
Dronedarone is a novel antiarrhythmic drug that can help 
patients return to and maintain sinus rhythm, control 
  ventricular response during recurrent episodes of atrial 
fibrillation, and reduce hospitalizations and cardiovascular 
mortality. These important clinical end points differ from 
other antiarrhythmic drugs as there have been no drugs to 
date, which have been able to reduce cardiovascular or total 
mortality in combination with hospitalization reduction. 
Dronedarone also has a low risk of adverse side effects and 
therefore appears to be relatively safe. Although it may be 
more expensive and more difficult to take given its twice 
daily dosing compared with amiodarone, for patients who 
are at risk for   developing significant amiodarone toxicity 
such as those who will need the drug for a long period of 
time and for younger,   otherwise healthy patients, this drug 
may have a vital role in the management of their symp-
toms and improvement in their long-term cardiovascular 
outcomes.
As we continue to learn about important clinical end 
points and we better understand the complexities of manag-
ing atrial fibrillation, dronedarone adds a new dimension Core Evidence 2010:5 submit your manuscript | www.dovepress.com
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to the treatment possibilities, at least for some patient 
populations. We look forward to the continued use of 
dronedarone in clinical practice to determine if it, like the 
mythical characters its studies are named for, can stand 
the test of time.
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